Zevra Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on the stock and has a $26.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Zevra Therapeutics’ strong performance and future potential. The company’s third-quarter 2025 results were positive, showing a significant increase in patient enrollments for Miplyffa, despite the inherent variability in ultra-orphan indication launches. The revenue for the quarter was robust, with Miplyffa contributing significantly, and the company is well-positioned for long-term growth through increased adoption in the U.S. and potential approval in the EU.
Furthermore, Zevra’s pipeline is progressing well, with the Marketing Authorisation Application for arimoclomol under review by the European Medicines Agency, which could open up a market opportunity comparable to the U.S. The ongoing Phase 3 DiSCOVER trial for the VEDS program is also advancing, with updates expected in 2026. Additionally, scientific engagement around Miplyffa continues to be strong, with recent studies reinforcing its efficacy and safety, supporting potential label expansion. These factors collectively support the Buy rating and a price target of $26.
According to TipRanks, Folkes is an analyst with an average return of -1.2% and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Eupraxia Pharmaceuticals, and Achieve Life Sciences.